Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Schmidt

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 7, 2004
The course of depressive illness in general practiceFrédéric Limosin, Jean-Yves Loze, Myriam Zylberman-Bouhassira, et al.
Neurology|December 20, 2013
PET imaging shows loss of striatal PDE10A in patients with Huntington diseaseRawaha Ahmad, Sophie Bourgeois, Andrey Postnov, et al.
Psychopharmacology|July 10, 2012
D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selectionMark E Schmidt, Peter de Boer, Randolph Andrews, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetineMelissa J Joliat, Mark E Schmidt, Maurizio Fava, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 18, 2022
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifierDawn C Matthews, Ana S Lukic, Randolph D Andrews, et al.
Nuclear Medicine and Biology|March 8, 2003
Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivoRikki N Waterhouse, Mark E Schmidt, Abida Sultana, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 12, 2013
Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brainKoen Van Laere, Rawaha U Ahmad, Hendra Hudyana, et al.
Alzheimer'S Research & Therapy|December 16, 2015
In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 miceAnn-Marie Waldron, Cindy Wintmolders, Astrid Bottelbergs, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2012
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imagingKoen Van Laere, Rawaha U Ahmad, Hendra Hudyana, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 7, 2004
The course of depressive illness in general practiceFrédéric Limosin, Jean-Yves Loze, Myriam Zylberman-Bouhassira, et al.
Neurology|December 20, 2013
PET imaging shows loss of striatal PDE10A in patients with Huntington diseaseRawaha Ahmad, Sophie Bourgeois, Andrey Postnov, et al.
Psychopharmacology|July 10, 2012
D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selectionMark E Schmidt, Peter de Boer, Randolph Andrews, et al.
The Journal of Clinical Psychiatry|April 21, 2004
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetineMelissa J Joliat, Mark E Schmidt, Maurizio Fava, et al.
Alzheimer'S & Dementia (New York, N. Y.)|July 18, 2022
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifierDawn C Matthews, Ana S Lukic, Randolph D Andrews, et al.
Nuclear Medicine and Biology|March 8, 2003
Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivoRikki N Waterhouse, Mark E Schmidt, Abida Sultana, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 12, 2013
Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brainKoen Van Laere, Rawaha U Ahmad, Hendra Hudyana, et al.
Alzheimer'S Research & Therapy|December 16, 2015
In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 miceAnn-Marie Waldron, Cindy Wintmolders, Astrid Bottelbergs, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2012
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imagingKoen Van Laere, Rawaha U Ahmad, Hendra Hudyana, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophreniaMark E Schmidt, Justine M Kent, Ella Daly, et al.
Pageof 7